Researchers have discovered an association between the spread of HIV and quantity of extracellular vesicles from lactobacilli, suggesting a protective mechanism to inhibit the spread of HIV infection.
Browsing: Basic > Pre-clinical Trials
Research published today in Infection and Immunity suggests a novel vaccine for Staphylococcus aureus may be on the horizon, with the candidate protecting 80% of immunized mice.
Researchers from the Wistar Institute have engineered a synthetic DNA vaccine able to provide potent immunity against the emerging Mayaro virus in mice models.
A biomimetic, micromotor vaccine formulation has shown promising results in immunizing against Staphylococcus aureus in mouse models.
An mRNA-based vaccine has been demonstrated to protect against Powassan virus in mice, in addition to also conferring protection against the more distantly related Langat virus.
Researchers have successfully used monoclonal antibodies to protect animal models from Candida infections for the first time, demonstrating their potential for treating this fungal disease.
Researchers from the University of Zurich have discovered that thanatin, a compound produced naturally by the spined soldier bug, could target Gram-negative bacteria by preventing formation of the bacteria’s outer membrane – an unprecedented mechanism.
Small molecules that block bacterial toxin formation have shown promise against Gram-positive bacteria in mouse models.
Experimental HIV-1 vaccine regimen is safe and elicits a robust immune response according to results of a Phase I/IIa clinical trial.
Recent technological advancements have allowed organoids to become a viable research tool for a wide range of development and disease models. Here, we look at some of the research that’s been done in infectious diseases and delve into what the future of organoids might look like.